Observational studyClinical oral investigations2023

Periodontal and cardiovascular therapies modify specialized pro-resolving lipid mediator (sPRLM) (LPXA4, PD1, RvE1, RvD1, and MaR1)-mediated pathway: the first pilot clinical study.

Kübra Karakoç Güvenç et al.PubMed ↗Publisher ↗

No numbers read from the abstract.